The significance of this work lies in that it provides preclinical evidence suggesting that mifepristone monotherapy can be an alternative to treat ovarian cancers intrinsically resistant to clinically achievable doses of cisplatin, or recurrent ovarian cancer tumors which frequently have become platinum resistant and lack p53 function. This evidence concerns the gene TP53 and ovarian carcinoma.